Head to Head Contrast: Profusa (NASDAQ:PFSA) versus Biosig Technologies (NASDAQ:STEX)

Profusa (NASDAQ:PFSA) and Biosig Technologies (NASDAQ:STEX) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Profusa and Biosig Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Biosig Technologies	1	0	0	0	1.00

Insider and Institutional Ownership

9.8% of Profusa shares are owned by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are owned by institutional investors. 11.4% of Profusa shares are owned by insiders. Comparatively, 52.7% of Biosig Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Profusa has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Profitability

This table compares Profusa and Biosig Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Biosig Technologies	N/A	N/A	-64.96%

Valuation & Earnings

This table compares Profusa and Biosig Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$8.71 million	($2.23)	-0.90
Biosig Technologies	$40,000.00	9,615.90	-$10.33 million	($1.35)	-1.79

Profusa has higher earnings, but lower revenue than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Summary

Biosig Technologies beats Profusa on 5 of the 8 factors compared between the two stocks.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.